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Background: The United Kingdom performs poorly in international comparisons of colorectal cancer survival with much of the
deficit owing to high numbers of deaths close to the time of diagnosis. This retrospective cohort study investigates the patient,
tumour and treatment characteristics of those who die in the first year after diagnosis of their disease.
Methods: Patients diagnosed with colon (n¼ 65 733) or rectal (n¼ 26 123) cancer in England between 2006 and 2008 were
identified in the National Cancer Data Repository. Multivariable logistic regression was used to investigate the odds of death
within 1 month, 1–3 months and 3–12 months after diagnosis.
Results: In all, 11.5% of colon and 5.4% of rectal cancer patients died within a month of diagnosis: this proportion decreased
significantly over the study period. For both cancer sites, older age, stage at diagnosis, deprivation and emergency presentation
were associated with early death. Individuals who died shortly after diagnosis were also more likely to have missing data about
important prognostic factors such as disease stage and treatment.
Conclusion: Using routinely collected data, at no inconvenience to patients, we have identified some important areas relating to
early deaths from colorectal cancer, which merit further research.
Five-year survival rates from colon and rectal cancer vary
significantly across Europe (Verdecchia et al, 2007), with outcomes
in the United Kingdom falling short of those seen in many
comparable European countries, such as Norway and Sweden.
Recent studies have demonstrated that this survival deficit is
primarily due to a relatively high number of excess deaths
occurring (mainly in older patients) in the first few months after
diagnosis (Engholm et al, 2007; Folkesson et al, 2009; Moller et al,
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2010; Morris et al, 2011). What has not been clear is why such a
high proportion of individuals in the United Kingdom die so
rapidly after diagnosis. Advanced stage of disease at presentation,
high levels of co-morbidity preventing active treatment, poor
quality of care and differences in access to gold-standard
treatments have all been suggested as potential explanations.
However, until recently, the paucity of population-level data
suitable to explore these factors has prevented an assessment of
their relative contribution to rapidly fatal disease. The establish-
ment by the National Cancer Intelligence Network (NCIN) of the
National Cancer Data Repository (NCDR) has done much to
address this (National Cancer Intelligence Network, 2011). This
study makes use of the NCDR to quantify at a population level the
patient, tumour and treatment characteristics of individuals with
colon and rectal cancer in England who died within 1 year of
diagnosis, in order to establish a clearer understanding of the
factors associated with early mortality.
METHODS
Information was extracted from the NCDR on all patients
diagnosed with a first primary colon (International Classification
of Diseases Version 10 (ICD10) (World Health Organisation,
2004) code C18-19) or rectal (ICD10 code C20) cancer in England
between 2006 and 2008. Patient and tumour information was
obtained from the cancer registry component of the NCDR.
Postcode of residence at diagnosis was used to measure socio-
economic background using the income domain of the 2004 Index
of Multiple Deprivation (Office of the Deputy Prime Minister,
2005).
A number of variables were derived using the linked data
available in the NCDR. A Charlson co-morbidity score (Charlson
et al, 1987) was calculated for each individual linked to Hospital
Episodes Statistics (HES) based on the diagnostic reasons for any
hospital admissions in the year preceding diagnosis of their
colorectal tumour. Patients were grouped into Charlson score
categories of 0, 1, 2 or X3 and unknown (if the patient could not
be identified in HES). A primary procedure (as defined by the
OPCS Classification of Interventions and Procedures version 4
(NHS Connecting for Health, 2009) was sought for every
individual identified in HES. A hierarchy of primary procedures
occurring within 12 months of diagnosis was established: major
resection; minor resection; palliative procedures. Individuals were
allocated to the highest category compatible with their HES
records. If no primary procedure could be identified, individuals
were allocated to the ‘no surgical treatment’ category. Individuals
that could not be identified in HES were included in a separate
‘unknown’ category. The method of presentation at hospital was
categorised as: elective; emergency or unknown by combining the
admission method from the relevant HES episodes with the ‘route
to diagnosis’ information from the NCDR (Elliss-Brookes et al,
2012). The ‘route to diagnosis’ uses multiple data sources to
characterise a ‘pathway’ to diagnosis, one of which is emergency
presentation.
Cases were split into groups by survival time after diagnosis:
p1 month (0–30 days), 1–3 months (31–90 days), 3–12 months
(91–365 days), alive at 1 year (4365 days). Logistic regression
was used to investigate the odds of death within 1 month, 1–3
months and 3–12 months after adjustment for patient, tumour
and treatment characteristics. Colon and rectal cancers were
analysed separately (see Supplementary Tables online for study
population characteristics). The colon cancer model was built with
a multi-level structure (with patients nested within cancer
registries) as cancer registry was a significant factor in the
single-level model.
RESULTS
During the study period 65 733 and 26 123 individuals were
diagnosed with colon or rectal cancer, respectively. Of those
diagnosed with colon cancer, 33.4% died within a year: 11.5%
within 1 month, 8.2% within 1–3 months and 13.7% within 3–12
months. For rectal cancer, the proportion dying within 12 months
of diagnosis was lower (24.8%): 5.4% died within a month of
diagnosis, 5.9% within 1–3 months and 13.5% within 3–12 months
(Figure 1).
For both the colon and rectal cancer populations, patients dying
within 1 month of diagnosis were more likely to be older, female,
have received no surgical treatment, have higher co-morbidity
scores, have more advanced disease and present as an emergency
(see Supplementary Tables online for the study population
characteristics). In addition, the proportion of cases missing
information on stage at diagnosis, co-morbidity, surgical treatment
or method of presentation was greater in those who died close to
the time of diagnosis.
The multivariable analysis for individuals with colon cancer
demonstrated a significant reduction in the odds of dying within 1
month of diagnosis in successive diagnosis years (OR 0.91, 95% CI:
0.88–0.94) but no change in the odds of dying between 1–3 and 3–
12 months from diagnosis. (Table 1) There was a positive
association between age and the odds of death within each survival
period. The odds of dying within 1 month of diagnosis were higher
amongst individuals who received palliative surgery (OR 1.26, 95%
CI: 1.10–1.45) or no surgical treatment (OR 2.68, 95% CI: 2.47–
2.91) compared with a surgical resection, but were greatest for the
unknown treatment category (OR 11.20, 95% CI: 10.07–12.46). In
the latter survival periods, the odds of death for this unknown
category reduced (but remained significant), whereas the odds
increased for both the palliative surgery and no surgery categories.
Increasing co-morbidity, deprivation and Dukes’ stage were
associated with increased odds of death in all three survival
periods. Individuals with no staging information had increased
odds of death in each period but this was greatest in the first
month after diagnosis (OR 8.11, 95% CI: 6.38–10.30 compared
with Dukes A). Finally, those presenting as an emergency had
significantly increased odds of early death.
The multivariable rectal cancer model results were very similar
to those for colon cancer (Table 2). The main differences were a
reduction in the odds of death over the study period within both
1 month and 1–3 months of diagnosis (OR 0.87, 95% CI: 0.81–0.95
and OR 0.91, 95% CI: 0.85–0.97, respectively per year increase) and
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Figure 1. Proportion of the colon and rectal cancer populations in
relation to the time from diagnosis until death.
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a 21-fold increase in the odds of dying within 1 month of diagnosis
in the unknown treatment category (OR 21.59, 95% CI: 17.03–
27.36 compared with having a resection).
DISCUSSION
This retrospective study found that individuals with both colon
and rectal tumours who died soon after their diagnosis were likely
to be elderly, live in more deprived areas, present as emergencies,
have advanced disease at diagnosis and fail to receive any radical
treatment. This is in line with evidence from several other
published studies from European populations (Engholm et al,
2007; Folkesson et al, 2009; Brewster et al, 2011; Morris et al, 2011;
Moller et al, 2012). The results also indicate that the odds of a very
early death (within a month of diagnosis) decreased over the study
period.
A new observation was the high proportion of missing data
amongst those who die very rapidly after diagnosis, especially for
stage of disease and treatment type. The reasons for this are
complex but might include no or limited contact with secondary
care owing to rapidly fatal disease, insufficient pathological and/or
radiological information for staging, failure to record information
in the patients’ notes and treatment in private hospitals
(not included in HES). Alternatively, the NCDR may be missing
relevant inpatient episodes for individuals whose cancer diagnosis
has been miscoded. Linkage between cancer registration data and
inpatient HES records within the NCDR is currently only available
for individuals for whom at least one episode of care contains a
Table 1. Multivariable analysis of individuals with colon cancer in relation to time from diagnosis
Odds of death
a
within
1 Month of diagnosis 1–3 Months of diagnosis 3–12 Months of diagnosis
Characteristic OR 95% CI OR 95% CI OR 95% CI
Year of diagnosis 0.91 0.88–0.94 0.97 0.94–1.01 0.98 0.95–1.01
Age at diagnosis 1.05 1.04–1.05 1.03 1.03–1.04 1.03 1.03–1.04
Sex
Male 1.00 1.00 1.00
Female 0.97 0.91–1.03 0.97 0.91–1.03 1.09 1.03–1.15
Surgical treatment
Resection 1.00 1.00 1.00
Palliative 1.26 1.10–1.45 2.51 2.22–2.84 5.19 4.65–5.80
No surgery 2.68 2.47–2.91 3.68 3.39–4.00 3.62 3.33–3.88
Unknown 11.20 10.07–12.46 3.05 2.62–3.55 1.84 1.58–2.14
Charlson co-morbidity score
0 1.00 1.00 1.00
1 1.48 1.37–1.60 1.08 0.99–1.18 1.30 1.21–1.41
2 1.69 1.51–1.89 1.42 1.26–1.62 1.41 1.26–1.59
X3 1.97 1.75–2.22 1.39 1.20–1.61 1.96 1.70–2.26
Unknownb Omitted Omitted Omitted
Index of Multiple Deprivation income category
Most affluent 1.00 1.00 1.00
2 1.10 1.01–1.21 1.11 1.00–1.22 1.09 1.01–1.19
3 1.13 1.03–1.24 1.15 1.04–1.27 1.14 1.05–1.24
4 1.26 1.15–1.38 1.23 1.12–1.36 1.18 1.08–1.29
Most deprived 1.30 1.18–1.43 1.28 1.16–1.43 1.24 1.14–1.36
Unknownb 1.65 1.31–2.08 1.13 0.86–1.48 1.18 0.95–1.47
Dukes’ stage at diagnosis
A 1.00 1.00 1.00
B 2.53 1.98–3.23 1.06 0.87–1.29 1.46 1.23–1.74
C 3.18 2.49–4.05 1.51 1.24–1.83 3.92 3.33–4.62
D 5.59 4.39–7.12 5.17 4.29–6.25 14.63 12.39–17.28
Unknown 8.11 6.38–10.30 3.23 2.67–3.91 6.27 5.29–7.42
Method of presentation
Elective 1.00 1.00 1.00
Emergency 4.24 3.98–4.51 2.03 1.90–2.16 1.79 1.69–1.89
Unknown 0.86 0.73–1.00 0.96 0.75–1.22 0.97 0.77–1.23
Abbreviations: CI¼ confidence interval; OR¼odds ratio.
aMutually adjusted for all characteristics listed.
bOmitted owing to collinearity with unknown surgical treatment.
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reference to cancer. A more comprehensive linkage using all
available HES data will in future enable the scale of this to be
established.
The NCDR contains population-based data for all colorectal
cancer patients diagnosed in England and this study includes over
90 000 individuals. Using these routinely collected data, at no
inconvenience to patients, we have identified some important areas
which merit further research. For example, do delays in
presentation, referral and diagnosis have a major role in early
deaths or do they arise simply as a result of more aggressive
disease? In addition, the reasons for the high proportion of missing
data in those dying soon after diagnosis need to be established. It is
not yet possible, however, to use the NCDR to fully answer these
questions as it does not contain the depth of information required,
such as details of primary care attendances or the dates that
symptoms first presented. The NCIN continues to work to increase
the scope of the NCDR, including linkage with general practitioner
records of attendance, but alongside this, detailed prospective
studies are required to provide a greater understanding of the pre-
morbid health and health care attendance of patients who die early
from colorectal cancer.
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